Page 53 - Read Online
P. 53
Page 14 of 15 Hall et al. Hepatoma Res. 2026;12:20
24. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons,
current challenges, and clinical perspectives: Hepatology. Hepatology. 2013;58:2188-97. DOI PubMed PMC
25. Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current
techniques in interventional radiology and personalized dosimetry. BJR. 2016;89:20150943. DOI PubMed PMC
26. Garin E, Tselikas L, Guiu B, et al. Long-term overall survival after selective internal radiation therapy for locally advanced
hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med. 2024;65:264-9. DOI PubMed PMC
27. Zhang R, Yao Y, Gao H, Hu X. Mechanisms of angiogenesis in tumour. Front. Oncol. 2024;14:1359069. DOI PubMed PMC
28. Wang L, Geng H, Liu Y, et al. Hot and cold tumors: immunological features and the therapeutic strategies. MedComm. 2023;4:e343.
DOI PubMed PMC
29. Gajewski TF, Schreiber H, Fu Y. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014-22.
DOI PubMed PMC
30. Tong J, Tan Y, Ouyang W, Chang H. Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies
with curative potential. Exp Hematol Oncol. 2025;14:65. DOI PubMed PMC
31. Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced
hepatocellular carcinoma. J Hepatol. 2019;71:1164-74. DOI
32. Öcal O, Schütte K, Zech CJ, et al. Addition of Y-90 radioembolization increases tumor response and local disease control in
hepatocellular carcinoma patients receiving sorafenib. Eur J Nucl Med Mol Imaging. 2022;49:4716-26. DOI PubMed PMC
33. Chow PK, Gandhi M, Tan S, et al. ; on behalf of Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: selective internal
radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913-21. DOI PubMed
34. Facciorusso A, Bargellini I, Cela M, Cincione I, Sacco R. Comparison between Y90 radioembolization plus sorafenib and Y90
radioembolization alone in the treatment of hepatocellular carcinoma: a propensity score analysis. Cancers. 2020;12:897. DOI PubMed
PMC
35. Qin S, Chen M, Cheng A, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk
hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2023;402:1835-47. DOI
PubMed
36. Hack SP, Spahn J, Chen M, et al. IMbrave 050: A phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma
after curative resection or ablation. Future Oncol. 2020;16:975-89. DOI
37. Yu S, Yu M, Keane B, et al. A pilot study of pembrolizumab in combination with y90 radioembolization in subjects with poor prognosis
hepatocellular carcinoma. The Oncologist. 2024;29:270-e413. DOI PubMed PMC
38. Tai D, Loke K, Gogna A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular
carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:1025-35. DOI
39. Fenton SE, Kircher SM, Mulcahy MF, et al. A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in
patients with advanced hepatocellular cancer. J Clin Oncol. 2021;39:e16183. DOI
40. Centers for Disease Control and Prevention. Study of [Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in
HCC for Liver Transplant]: NCT07059494. CDC. Updated November 4, 2025. https://clinicaltrials.gov/study/NCT07059494. [Accessed
on 20 May 2026].
41. Centers for Disease Control and Prevention. Study of [Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy
Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma]:
NCT06867432. CDC. Updated March 10, 2025. https://clinicaltrials.gov/study/NCT06867432. [Accessed on 20 May 2026].
42. Centers for Disease Control and Prevention. Study of [Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma]:
NCT05809869. CDC. Updated April 12, 2024. https://clinicaltrials.gov/study/NCT05809869. [Accessed on 20 May 2026].
43. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a
comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64. DOI
44. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with
chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. DOI PubMed PMC
45. Jones A, Degregorio P, Sung MW, Ramji Z, Ren M, Baron AD. Characterization and management of adverse reactions in patients with
unresectable hepatocellular carcinoma treated with lenvatinib. JADPRO. 2023;14:598-607. DOI PubMed PMC
46. Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90 +/− sorafenib as bridge to transplantation in
hepatocellular carcinoma. J Hepatol. 2014;61:309-17. DOI
47. Ramos-casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers.
2020;6:38. DOI PubMed PMC
48. Zhan C, Ruohoniemi D, Shanbhogue KP, et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor
immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31:25-34. DOI
